Radical metastasectomy followed by sorafenib versus observation in patients with clear cell renal cell carcinoma: extended follow up of efficacy results from the randomized phase II RESORT trial.

Background: The RESORT trial showed no longer relapse free survival (RFS) with sorafenib following radical metastasectomy versus observation in metastatic renal cell carcinoma patients. We present the updated 42-month follow up data.